Online citations, reference lists, and bibliographies.
Referencing for people who value simplicity, privacy, and speed.
Get Citationsy
← Back to Search

Plasma 1,25-Dihydroxy- And 25-Hydroxyvitamin D And Subsequent Risk Of Prostate Cancer

E. Platz, M. Leitzmann, B. Hollis, W. Willett, E. Giovannucci
Published 2004 · Medicine

Save to my Library
Download PDF
Analyze on Scholarcy Visualize in Litmaps
Reduce the time it takes to create your bibliography by a factor of 10 by using the world’s favourite reference manager
Time to take this seriously.
Get Citationsy
AbstractObjective: The hormone 1,25-dihydroxyvitamin D (1,25(OH)2D) promotes prostate epithelial cell differentiation in vitro and thus, several groups have hypothesized that men who systemically have lower levels of 1,25(OH)2D may be at increased risk for prostate cancer. To address this hypothesis, we evaluated the association of circulating concentrations of 1,25(OH)2D and its precursor 25-hydroxyvitamin D (25(OH)D) with subsequent risk of prostate cancer. Methods: Prostate cancer cases were 460 men in the Health Professionals Follow-up Study who were diagnosed through 1998 after providing a blood specimen in 1993/95. 90.2% of the cases were organ confined or had minimal extraprostatic extension. An equal number of controls who had had a screening PSA test after blood draw were individually matched to cases on age, history of a PSA test before blood draw, and time of day, season, and year of blood draw. Plasma 1,25(OH)2D and 25(OH)D concentrations were determined by radio-immunosorbant assay blindly to case–control status. Odds ratios (OR) of prostate cancer and 95% confidence intervals (CI) were estimated from conditional logistic regression models mutually adjusting for quartiles of 1,25(OH)2D and 25(OH)D concentrations and for suspected prostate cancer risk factors. Quartile cutpoints were determined separately by season of blood draw using the distributions among controls. Results: Mean concentrations of 1,25(OH)2D and 25(OH)D were slightly, but not statistically significantly (p= 0.06 and 0.20, respectively), higher in cases (34.3 ± 7.1 pg/ml and 24.6 ± 7.7 ng/ml, respectively) than in controls (33.5 ± 7.1 pg/ml and 23.9 ± 8.2 ng/ml, respectively). The OR of prostate cancer comparing men in the top to bottom quartile of 1,25(OH)2D was 1.25 (95% CI: 0.82–1.90, p-trend = 0.16). For 25(OH)D the OR of prostate cancer comparing the top and bottom quartiles was 1.19 (95% CI: 0.79–1.79, p-trend = 0.59). These findings did not vary by level of the other metabolite, age at diagnosis, family history of prostate cancer, or factors that are thought to influence 25(OH)D levels. Conclusion: In this prospective study, we did not observe an inverse association between plasma concentrations of 1,25(OH)2D or 25(OH)D and incident prostate cancer, although we cannot rule out potential effects at later stages of the disease.
This paper references
Inhibition of human prostatic carcinoma cell lines by 1,25 dihydroxyvitamin D3 and vitamin D analogs
RR Bahnson (1993)
Chemopreventive activity of tamoxifen, N-(4-hydroxyphenyl)retinamide, and the vitamin D analogue Ro24-5531 for androgen-promoted carcinomas of the rat seminal vesicle and prostate.
M. S. Lucia (1995)
Vitamin D and prostate cancer: 1,25 dihydroxyvitamin D3 receptors and actions in human prostate cancer cell lines.
R. Skowroński (1993)
Stable expression of the nuclear vitamin D receptor in the human prostatic carcinoma cell line JCA-1: evidence that the antiproliferative effects of 1 alpha, 25-dihydroxyvitamin D3 are mediated exclusively through the genomic signaling pathway.
T. Hedlund (1996)
The role of the vitamin D endocrine system in health and disease.
H. Reichel (1989)
Prostate cancer and prediagnostic levels of serum vitamin D metabolites (Maryland, United States)
M. Braun (2004)
Test of the National Death Index.
M. Stampfer (1984)
Dairy products, calcium, phosphorous, vitamin D, and risk of prostate cancer (Sweden)
J. Chan (2004)
IGF - binding proteins in human
RH Drivdahl (1995)
Regulation of growth, PSA/PAP and androgen receptor expression by 1 alpha,25-dihydroxyvitamin D3 in the androgen-dependent LNCaP cells.
T. Hsieh (1996)
Vitamin D receptor expression, 24-hydroxylase activity, and inhibition of growth by 1alpha,25-dihydroxyvitamin D3 in seven human prostatic carcinoma cell lines.
G. Miller (1995)
Diet and prostate cancer risk in a cohort of smokers, with a specific focus on calcium and phosphorus (Finland)
J. Chan (2004)
Is the Recommended Daily Allowance for Vitamin D Too Low for the Homebound Elderly?
F. M. Gloth (1991)
tumor cells : expression and regulation by 1 , 25 - dihydroxyvitamin D 3
M Esquenet (1996)
Prostate cancer risk and prediagnostic serum 25-hydroxyvitamin D levels (Finland)
M. Ahonen (2004)
1,25-Dihydroxyvitamin D3 decreases human prostate cancer cell adhesion and migration
Victoria Sung (2000)
Determination of vitamin D status by radioimmunoassay with an 125I-labeled tracer.
B. Hollis (1993)
Antiproliferative effects of 1,25-dihydroxyvitamin D3 on primary cultures of human prostatic cells.
D. Peehl (1994)
Human prostate cells synthesize 1,25-dihydroxyvitamin D3 from 25-hydroxyvitamin D3.
G. Schwartz (1998)
1,25-Dihydroxy-16-ene-23-yne-vitamin D3 and prostate cancer cell proliferation in vivo.
G. Schwartz (1995)
Is vitamin D deficiency a risk factor for prostate cancer? (Hypothesis).
G. Schwartz (1990)
Taber's Cyclopedic Medical Dictionary (Book)
Valerie Parham (1998)
Control of LNCaP proliferation and differentiation: Actions and interactions of androgens, Iα,25‐dihydroxycholecalciferol, all‐trans retinoic acid, 9‐cis retinoic acid, and phenylacetate
M. Esquenet (1996)
Serum vitamin D metabolite levels and the subsequent development of prostate cancer (Hawaii, United States)
A. Nomura (2004)
Circulating vitamin D metabolites in relation to subsequent development of prostate cancer.
P. Gann (1996)
Vitamin D and prostate cancer: a prediagnostic study with stored sera.
E. Corder (1993)
Quantification of circulating 1,25-dihydroxyvitamin D by radioimmunoassay with 125I-labeled tracer.
B. Hollis (1996)
Regulation of the metabolism of vitamin D.
D. R. Fraser (1980)
Calcium and fructose intake in relation to risk of prostate cancer.
E. Giovannucci (1998)
IGF‐Binding proteins in human prostate tumor cells: Expression and regulation by 1,25‐dihydroxyvitamin D3
R. Drivdahl (1995)

This paper is referenced by
The Relationship between Plasma Vitamin D Level and Heart Valves Calcification
K. FeldmanViktor (2020)
Hiperparatiroidismo secundario en el cáncer de próstata avanzado
Susana Quirosa Flores (2010)
Selenium and prostate cancer: systematic review and meta-analysis.
R. Hurst (2012)
Epidemiology of vitamin D in health and disease
S. Wang (2009)
Vitamin D gene pathway polymorphisms and risk of colorectal, breast, and prostate cancer.
M. McCullough (2009)
Height and Prostate Cancer Risk: A Large Nested Case-Control Study (ProtecT) and Meta-analysis
L. Zuccolo (2008)
Intratumoral Sterol-27-Hydroxylase (CYP27A1) Expression in Relation to Cholesterol Synthesis and Vitamin D Signaling and Its Association with Lethal Prostate Cancer
N. Khan (2019)
A Prospective Study of Calcium Intake and Incident and Fatal Prostate Cancer
E. Giovannucci (2006)
Vitamin D and prostate cancer risk: a review of the epidemiological literature
D. Gupta (2009)
Nutraceuticals and prostate cancer prevention: a current review
Greg Trottier (2010)
Vitamin D receptor (VDR) gene polymorphisms and haplotypes, interactions with plasma 25‐hydroxyvitamin D and 1,25‐dihydroxyvitamin D, and prostate cancer risk
B. Mikhak (2007)
Vitamin D Deficiency Predicts Prostate Biopsy Outcomes
A. Murphy (2014)
Cohort Consortium Vitamin D Pooling Project of Rarer Cancers
M. McCullough (2010)
Prostate cancer and vitamin D: what does the evidence really suggest?
C. Barnett (2011)
Physical activity, sedentary behavior, and vitamin D metabolites.
Elizabeth A. Hibler (2016)
Vitamin D, PTH, and calcium and tumor aggressiveness in prostate cancer: a prospective nested case–control study
Johan Brändstedt (2015)
Vitamin D and Sunlight Exposure in Newly-Diagnosed Parkinson’s Disease
J. Wang (2016)
Association of low serum 25-hydroxyvitamin D levels and acute kidney injury in the critically ill*
A. Braun (2012)
Plasma 25-Hydroxyvitamin D Levels and Risk of Incident Hypertension
J. Forman (2007)
Role of Hormonal and Other Factors in Human Prostate Cancer
D. T. Wigle (2008)
Calcium intake and vitamin D metabolism and action, in healthy conditions and in prostate cancer.
J. Bonjour (2007)
Associations of circulating and dietary vitamin D with prostate cancer risk: a systematic review and dose–response meta-analysis
R. Gilbert (2010)
Serum Calcium Concentration and Prostate Cancer Risk: A Multicenter Study
S. Salem (2013)
Vitamin D in health and disease: an insight into traditional functions and new roles for the ‘sunshine vitamin’
D. Borradale (2009)
Nutrient- and Drug- Responsive Polymorphic Genes as Nutrigenomic Tools for Prevention of Cardiovascular Disease and Cancer
M. Bakovic (2006)
Association of Circulating 25(OH)D and Lower Urinary Tract Symptoms: A Four-Year Prospective Study among Elderly Chinese Men
Zhao-min Liu (2016)
Vitamin D and prostate cancer risk--a less sunny outlook?
L. Mucci (2008)
Association of Low Serum 25-Hydroxyvitamin D Levels and Sepsis in the Critically Ill
T. Moromizato (2014)
Sun exposure, vitamin D receptor gene polymorphisms, and risk of advanced prostate cancer.
E. John (2005)
Serum 25-Hydroxyvitamin D and Risk of Oropharynx and Larynx Cancers in Finnish Men
H. Arem (2011)
Circulating 25-Hydroxyvitamin D and Risk of Kidney Cancer
L. Gallicchio (2010)
Lack of Association between Serum Levels of 25-Hydroxyvitamin D and the Subsequent Risk of Prostate Cancer in Finnish Men
J. Faupel-Badger (2007)
See more
Semantic Scholar Logo Some data provided by SemanticScholar